Ethics in oncology: consulting for the investment industry.

Berlin J, Bruinooge SS, Tannock IF
J Clin Oncol. 2007 25 (4): 444-6

PMID: 17264341 · DOI:10.1200/JCO.2006.10.3036

As Ethics Committee Chair, I am pleased to introduce the first in an ongoing series of ethics vignettes. These columns, which are based on true-to-life situations that arise in oncology research and practice, are intended to identify and explore important ethical issues and provide commentary that is specific to oncology. Please look for them periodically in both the Journal of Clinical Oncology and the Journal of Oncology Practice. The idea for publishing vignettes evolved through the joint efforts of the Ethics Committee and the Board of Directors. Rather than adopt a single set of ethical principles that applies vaguely to any situation and well to none, the Committee and the Board preferred to tackle ethical dilemmas individually, specifically, and directly. Because the Ethics Committee thought the ethical and legal implications of physician interactions with the investment industry were so important and timely, it chose to address this topic in both a position article, which was previously published in the January 20, 2007, issue of the Journal of Clinical Oncology (J Clin Oncol 25:338-340, 2007) and in its first vignette column. The Ethics Committee hopes this column will be the first of several that ASCO members will find helpful as they grapple with the many ethical issues that arise in daily practice in the field of oncology. Because these columns are intended to address the concerns of ASCO members, the Committee welcomes suggestions for future topics at vignettes@asco.org. Martin D. Abeloff, MD, Chair, Ethics Committee.

MeSH Terms (12)

Antineoplastic Agents Clinical Trials as Topic Commerce Conflict of Interest Consultants Drug Industry Ethics, Professional Forecasting Humans Investments Medical Oncology Physician's Role

Connections (1)

This publication is referenced by other Labnodes entities:

Links